What's in Sichuan Baili Pharmaceutical Co., Ltd.'s pipeline?

Sichuan Baili Pharmaceutical Co., Ltd. has 21 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 3 in Phase 2, 12 in Phase 1.

Which companies overlap with Sichuan Baili Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: AstraZeneca, Novartis, Eurofarma Laboratorios S.A., AJU Pharm Co., Ltd., Abbott.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sichuan-baili-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sichuan Baili Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sichuan Baili Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 5 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 3 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Nifekalant hydrochloride	Nifekalant hydrochloride	marketed
Pemetrexed+Cisplatin or Carboplatin	Pemetrexed+Cisplatin or Carboplatin	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)	Oncology
SI-B001	SI-B001	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Liposomal doxorubicin, Paclitaxel or Topotecan	Liposomal doxorubicin, Paclitaxel or Topotecan	phase 3	Chemotherapy combination (anthracycline, taxane, camptothecin analog)	DNA (doxorubicin), β-tubulin (paclitaxel), Topoisomerase I (topotecan)	Oncology
BL-B01D1	BL-B01D1	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
BL-M07D1	BL-M07D1	phase 3		target

Therapeutic area mix

Diabetes · 2
Oncology · 2
Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
Novartis · 2 shared drug classes
Eurofarma Laboratorios S.A. · 2 shared drug classes
AJU Pharm Co., Ltd. · 1 shared drug class
Abbott · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
ATS Clinical Research · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sichuan Baili Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sichuan Baili Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sichuan-baili-pharmaceutical-co-ltd. Accessed 2026-05-17.